Tags

Type your tag names separated by a space and hit enter

Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.
Transfusion. 2020 08; 60(8):1765-1772.T

Abstract

BACKGROUND

The lack of effective treatments against the 2019 coronavirus disease (COVID-19) has led to the exploratory use of convalescent plasma for treating COVID-19. Case reports and case series have shown encouraging results. This study investigated SARS-CoV-2 antibodies and epidemiological characteristics in convalescent plasma donors, to identify criteria for donor selection.

METHODS

Recovered COVID-19 patients, aged 18-55 years, who had experienced no symptoms for more than 2 weeks, were recruited. Donor characteristics such as disease presentations were collected and SARS-CoV-2 N-specific IgM, IgG, and S-RBD-specific IgG levels were measured by enzyme-linked immunosorbent assay (ELISA).

RESULTS

Whereas levels of N-specific IgM antibody declined after recovery, S-RBD-specific and N-specific IgG antibodies increased after 4 weeks from the onset of symptoms, with no significant correlation to age, sex, or ABO blood type. Donors with the disease presentation of fever exceeding 38.5°C or lasting longer than 3 days exhibited higher levels of S-RBD-specific IgG antibodies at the time of donation. Of the 49 convalescent plasma donors, 90% had an S-RBD-specific IgG titer of ≥1:160 and 78% had a titer of ≥1:640 at the time of plasma donation. Of the 30 convalescent plasma donors, who had donated plasma later than 28 days after the onset of symptoms and had a disease presentation of fever lasting longer than 3 days or a body temperature exceeding 38.5°C, 100% had an S-RBD-specific IgG titer of ≥1:160 and 93% had a titer of ≥1:640.

CONCLUSION

This study indicates that the S-RBD-specific IgG antibody reaches higher levels after 4 weeks from the onset of COVID-19 symptoms. We recommend the following selection criteria for optimal donation of COVID-19 convalescent plasma: 28 days after the onset of symptoms and with a disease presentation of fever lasting longer than 3 days or a body temperature exceeding 38.5°C. Selection based on these criteria can ensure a high likelihood of achieving sufficiently high S-RBD-specific IgG titers.

Authors+Show Affiliations

Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan, China. Key Laboratory of Transfusion Adverse Reactions, CAMS, Chengdu, Sichuan, China.Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Respiratory Quality Control Center, National Center of Gerontology, Beijing, China.Wuhan Blood Center, Wuhan, Hubei, China.Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan, China. Key Laboratory of Transfusion Adverse Reactions, CAMS, Chengdu, Sichuan, China.Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan, China. Key Laboratory of Transfusion Adverse Reactions, CAMS, Chengdu, Sichuan, China.Wuhan Blood Center, Wuhan, Hubei, China.Wuhan Blood Center, Wuhan, Hubei, China.Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan, China. Key Laboratory of Transfusion Adverse Reactions, CAMS, Chengdu, Sichuan, China.Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan, China. Key Laboratory of Transfusion Adverse Reactions, CAMS, Chengdu, Sichuan, China.Wuhan Blood Center, Wuhan, Hubei, China.Wuhan Blood Center, Wuhan, Hubei, China.Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan, China. Key Laboratory of Transfusion Adverse Reactions, CAMS, Chengdu, Sichuan, China.Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan, China. Key Laboratory of Transfusion Adverse Reactions, CAMS, Chengdu, Sichuan, China.Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan, China. Key Laboratory of Transfusion Adverse Reactions, CAMS, Chengdu, Sichuan, China.State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.University of Miami, Miami, Florida, USA.Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan, China. Key Laboratory of Transfusion Adverse Reactions, CAMS, Chengdu, Sichuan, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32627216

Citation

Li, Ling, et al. "Characteristics and Serological Patterns of COVID-19 Convalescent Plasma Donors: Optimal Donors and Timing of Donation." Transfusion, vol. 60, no. 8, 2020, pp. 1765-1772.
Li L, Tong X, Chen H, et al. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion. 2020;60(8):1765-1772.
Li, L., Tong, X., Chen, H., He, R., Lv, Q., Yang, R., Zhao, L., Wang, J., Xu, H., Liu, C., Chen, G., Chen, S., Li, C., Qiao, J., Yang, J., Wu, Y., & Liu, Z. (2020). Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion, 60(8), 1765-1772. https://doi.org/10.1111/trf.15918
Li L, et al. Characteristics and Serological Patterns of COVID-19 Convalescent Plasma Donors: Optimal Donors and Timing of Donation. Transfusion. 2020;60(8):1765-1772. PubMed PMID: 32627216.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. AU - Li,Ling, AU - Tong,Xunliang, AU - Chen,Hanwei, AU - He,Rui, AU - Lv,Qilu, AU - Yang,Ru, AU - Zhao,Lei, AU - Wang,Jue, AU - Xu,Haixia, AU - Liu,Chuanqiao, AU - Chen,Guoan, AU - Chen,Sitian, AU - Li,Chenyue, AU - Qiao,Jiajia, AU - Yang,Juntao, AU - Wu,Yanyun, AU - Liu,Zhong, Y1 - 2020/07/06/ PY - 2020/04/24/received PY - 2020/05/07/revised PY - 2020/05/07/accepted PY - 2020/7/7/pubmed PY - 2020/11/11/medline PY - 2020/7/7/entrez SP - 1765 EP - 1772 JF - Transfusion JO - Transfusion VL - 60 IS - 8 N2 - BACKGROUND: The lack of effective treatments against the 2019 coronavirus disease (COVID-19) has led to the exploratory use of convalescent plasma for treating COVID-19. Case reports and case series have shown encouraging results. This study investigated SARS-CoV-2 antibodies and epidemiological characteristics in convalescent plasma donors, to identify criteria for donor selection. METHODS: Recovered COVID-19 patients, aged 18-55 years, who had experienced no symptoms for more than 2 weeks, were recruited. Donor characteristics such as disease presentations were collected and SARS-CoV-2 N-specific IgM, IgG, and S-RBD-specific IgG levels were measured by enzyme-linked immunosorbent assay (ELISA). RESULTS: Whereas levels of N-specific IgM antibody declined after recovery, S-RBD-specific and N-specific IgG antibodies increased after 4 weeks from the onset of symptoms, with no significant correlation to age, sex, or ABO blood type. Donors with the disease presentation of fever exceeding 38.5°C or lasting longer than 3 days exhibited higher levels of S-RBD-specific IgG antibodies at the time of donation. Of the 49 convalescent plasma donors, 90% had an S-RBD-specific IgG titer of ≥1:160 and 78% had a titer of ≥1:640 at the time of plasma donation. Of the 30 convalescent plasma donors, who had donated plasma later than 28 days after the onset of symptoms and had a disease presentation of fever lasting longer than 3 days or a body temperature exceeding 38.5°C, 100% had an S-RBD-specific IgG titer of ≥1:160 and 93% had a titer of ≥1:640. CONCLUSION: This study indicates that the S-RBD-specific IgG antibody reaches higher levels after 4 weeks from the onset of COVID-19 symptoms. We recommend the following selection criteria for optimal donation of COVID-19 convalescent plasma: 28 days after the onset of symptoms and with a disease presentation of fever lasting longer than 3 days or a body temperature exceeding 38.5°C. Selection based on these criteria can ensure a high likelihood of achieving sufficiently high S-RBD-specific IgG titers. SN - 1537-2995 UR - https://www.unboundmedicine.com/medline/citation/32627216/Characteristics_and_serological_patterns_of_COVID_19_convalescent_plasma_donors:_optimal_donors_and_timing_of_donation_ L2 - https://doi.org/10.1111/trf.15918 DB - PRIME DP - Unbound Medicine ER -